topic

716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer
Ecaterina Dumbrava, Joan Albanell Mestres, Paolo Antonio Ascierto, Jean-Yves Blay, Stéphane Champiat, Alfonso Cortes Salgado, Antoine Deleuze, Marta GilMartin, Arielle Heeke, Antoine Italiano, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Agnese Losurdo, Michele Magni, Kathleen Moore, Ana Oaknin Benzaquen, Ignacio Ortego Zabalza, Haeseong Park, Luis Paz-Ares Rodriguez, Mark D Pegram, Mariano Ponz-Sarvise, Drew Rasco, Manish Sharma, Ardaman Shergill, Jean-Philippe Spano, Alexander I Spira, Cecile Vicier, Ivan Victoria, Benjamin Weinberg, Coya Tapia, Jason Ptacek, Michael N Alonso, Lu Xu, Ming Yin, Edith A Perez, Bob T Li

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A811; DOI: 10.1136/jitc-2023-SITC2023.0716
717 A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: interim results from dose escalation
Sophia Frentzas, Elizabeth Ahern, Andrew Weickhardt, Andrew Haydon, John Powderly, Drew Rasco, Meredith McKean, Paul de Souza, Timothy Wyant, Jenny Tang, Lori Richards, Aron Knickerbocker, Inbar Amit, Yanay Ofran, James Vasselli

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A812; DOI: 10.1136/jitc-2023-SITC2023.0717
718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies
Benjamin Garmezy, Swetha Kambhampati, Brendan Curti, Melissa Reimers, Paolo Caimi, Catherine Diefenbach, Elisabeth Heath, Eric Jonasch, Stephen Park, Noah Kornblum, Weidong Li, Ning Li, Stephen Spurgeon, Ulka N Vaishampayan, Dingwei Ye, Li Zhang, Weili Zhao, Zhu Chen, Naomi Hunder, Sharon Ma, Eric Song, Justin A Call

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A813; DOI: 10.1136/jitc-2023-SITC2023.0718
719 Phase 1 clinical trial design of ZM008, a first-in-class anti LLT1 antibody is a promising therapy for multiple solid cancers
Maloy Ghosh, Anurag Tiwari, Ashvini Kumar Dubey, Sanghamitra Bhattacharjee, Yogendra Manjunath, Shalini Kashipathi, Subith Krishna, Tirtha Mandal, Soorya Gnanasegaran, Ignacio Garcia-Ribas

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A814; DOI: 10.1136/jitc-2023-SITC2023.0719
720 A phase 1/2 study of BDC-3042, a novel Dectin-2 agonistic antibody, in patients with advanced cancers
Antonio Giordano, Ecaterina Dumbrava, Aparna R Parikh, Justin Kenkel, Danlin Cai, Damon Demady, Lu Xu, Michael N Alonso, Shelley E Ackerman, Edith A Perez, Sharon Wilks

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A815; DOI: 10.1136/jitc-2023-SITC2023.0720
721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumors
Carlos Gomez-Roca, Neeltje Steeghs, Eelke Gort, Hilde De Winter, Elena Fernandez, Vaia Stavropoulou, Nina Stojcheva, Paul Baverel, Jennifer Krieg, Kyriaki Ioannou, Ana Maria Florescu, Lea Hoenig, Bruno Baud-Berthier, Michael P Sanderson, Vladimir Kirkin, Anne Goubier, Philippe Legenne, Philippe Cassier

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A816; DOI: 10.1136/jitc-2023-SITC2023.0721
722 Evaluation of the effects of pembrolizumab alone and in combination(s) with MDSC-targeting agents MK-0482 and MK-4830 on the native cancer patient TME via functional spatial profiling (CIVO®)
Kenneth Gundle, Karthik Rajasekaran, Jeffrey Houlton, Daniel Clayburgh, Michael Wagner, Elyse Brinkmann, Cherie-Ann Nathan, John Pang, Annemieke Van Zante, Jessica Davis, Connor Burns, Jason Frazier, Emily Beirne, Angela Merrell, Bre Mills, Jonathan Derry, Hanrong Sang, Atticus Turner, Marc Grenley, Nathan Schauer, Wendy Jenkins, Richard Klinghoffer

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A817; DOI: 10.1136/jitc-2023-SITC2023.0722
723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning
Martin Gutierrez, Michele Donato, Ronit Reich-Slotky, Sunil Patel, Morgan Finlay, Research Nurse Coordinator, Lawrence G Lum, Jee Hyun Park, Tania Felizardo, Daniel H Fowler

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A818; DOI: 10.1136/jitc-2023-SITC2023.0723
724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)
Omid Hamid, Sarina A Piha-Paul, Stephen V Liu, Ralph Boccia, Justin A Call, Trisha M Wise-Draper, Angela Tatiana Alistar, Anthony J Olszanski, John Wrangle, Anthony F Shields, Aranzazu Manzano, Emiliano Calvo, Shwetha Asha, Yangchun Du, Carlos Mayo, Leah Rider, Marc S Ernstoff

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A819; DOI: 10.1136/jitc-2023-SITC2023.0724
725 Preliminary results of a prospective pilot study using CD8 ImmunoPET imaging to evaluate the immune response to radiation therapy (ELIXR)
Claire Hao, Colton Ladbury, Paul Frankel, William T Watkins, Sumanta Pal, Jeffrey Wong, Saro Manoukian, Maria Parayno, William Le, Gareth Smith, Michael Ferris, Kristin Schmiedehausen, Anna Wu, Savita Dandapani

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A820; DOI: 10.1136/jitc-2023-SITC2023.0725

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages